The Emergence of Psilocybin in Psychiatry and Neuroscience

Psilocybin, a naturally occurring psychedelic compound, is being re-evaluated for its potential to treat psychiatric and neurological disorders. This review examines its pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Emerging evidence supports its effectiveness for major depressive disorder, treatment-resistant depression, anxiety, alcohol use disorders, and cancer-related distress. However, significant barriers remain, including methodological limitations, regulatory hurdles, and a lack of diversity in clinical trial populations. Advances in biosynthetic production and better psychotherapeutic integration are needed for scalability. Future research should focus on long-term safety, precise dosing, and neurobiological mechanisms to refine therapeutic applications.

Study at a glance

Abstract

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), and cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, and limited population diversity in clinical trials. Advances in biosynthetic production and optimized psychotherapeutic integration are necessary to ensure scalability and accessibility. Future research should focus on long-term safety, dosing precision, and neurobiological mechanisms to refine its therapeutic applications. This review provides a critical foundation for advancing evidence-based clinical integration of psilocybin.